Mainstream

Trevi Therapeutics outlines $204M cash runway into 2029 as Phase III programs advance following positive CORAL data

Trevi Therapeutics outlines $204M cash runway into 2029 as Phase III programs advance following positive CORAL data

Post ContenttrviRead More

You might also be interested in reading Scotia Responsible Investing Canadian Bond Index ETF declares CAD 0.045 dividend.

August 8, 2025
In Mainstream